Dr. Janice Reichert, Chief Operating Officer of The Antibody Society, is an internationally-recognized expert in the development of antibody therapeutics. She is Founder and Editor-in-Chief of mAbs, a peer-reviewed, PubMed-indexed biomedical journal that focuses on topics relevant to antibody research and development. Dr. Reichert has published extensively on development trends for antibody therapeutics, and she has presented her research results as an invited speaker at conferences held worldwide. She is co-editor of the Handbook of Therapeutic Antibodies, and serves on the editorial boards of several biomedical journals.
Dr. Reichert received her PhD in Chemistry from the University of Pennsylvania and did her post-doctoral training at Harvard Medical School.
Dr. Silvia Crescioli is a senior post doc at King’s College London in Prof. Sophia Karagiannis’ Cancer Antibody Discovery & Immunotherapy Group, where she leads and supervises several projects focused on different areas of cancer immunology and immunotherapy, such as the study of B cells in cancer, antigen/antibody discovery, ADC development, and antibody production, engineering and glycoengineering. Dr. Crescioli received her PhD in Biomedical Sciences, Experimental Oncology, from the University of Florence.
Dr. Alicia Chenoweth is a postdoctoral research associate in the Cancer Antibody Discovery and Immunotherapy group led by Prof. Sophia Karagiannis at King’s College London. Her work is focused on Fc engineering of antibodies for breast cancer therapy to better engage and influence the immune microenvironment. She received her PhD in Melbourne, Australia, under the supervision of Prof. Mark Hogarth, focusing on the interactions of human and non-human primate IgG antibodies with Fc receptors, and the impact of IgG Fc modification on immune cell function. Dr. Chenoweth was co-chair of the Gordon Research Seminar for Antibody Biology and Engineering, held in 2022.
Dr. Jyothsna Visweswaraiah is a scientist with drug development experience in small biotech and a track record of advancing new therapies into the clinic. She currently heads the Antibody Discovery group in the Drug Creation department at Seismic Therapeutic. She was previously at FL75, developing a modular, multi-specific biologics platform to address the complexities of biology with high resolution, and at Pandion Therapeutics where she developed novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Dr. Visweswaraiah has trained at Harvard Medical School and the National Institutes of Health. She has been an advocate for women in science and workplace inclusiveness. She mentors students interested in STEM careers, early career women scientists and serves on the Advisory Board of WEST, a non-profit organization supporting early to mid-career women. In recognition of her accomplishments, Dr. Visweswaraiah was nominated for the 2021 James S. Huston Antibody Science Talent Award.